D
Deleted member 431298
Guest
This thread is dedicated to discussions regarding the top-line results of the RHB-104 antibiotic pill conducted by Redhill Biopharma.
The results are due in july 2018, and the research outcome will cast more light on whether an infection with Mycobacterium Avium Ssp. Paratuberculosis (MAP) can cause / sustain Crohns disease in humans.
Selby et.al made a similar study back in 2003 but with a slightly different combination of antibiotics. The conclusion was initially that no effect was found, but later the conclusion was put into question, and a re-analysis concludes that the antibiotics did help induce remission.
The ambiguity of that study is what makes this new study by Redhill so interesting. If the researchers make a rigorous and credible analysis we will finally get an answer to the question: Can the treatment of a MAP infection lead to remission of Crohns Disease?
Results are in soon and will be posted here when they arrive so we can discuss their implications.
The results are due in july 2018, and the research outcome will cast more light on whether an infection with Mycobacterium Avium Ssp. Paratuberculosis (MAP) can cause / sustain Crohns disease in humans.
Selby et.al made a similar study back in 2003 but with a slightly different combination of antibiotics. The conclusion was initially that no effect was found, but later the conclusion was put into question, and a re-analysis concludes that the antibiotics did help induce remission.
The ambiguity of that study is what makes this new study by Redhill so interesting. If the researchers make a rigorous and credible analysis we will finally get an answer to the question: Can the treatment of a MAP infection lead to remission of Crohns Disease?
Results are in soon and will be posted here when they arrive so we can discuss their implications.